A randomized, double-bind, placebo-controlled, parallel-group, fixed-dose, multicenter study to assess efficacy and safety of rimonabant 20 mg versus placebo on weight loss and frequency of binge episodes in obese patients with food craving.

Trial Profile

A randomized, double-bind, placebo-controlled, parallel-group, fixed-dose, multicenter study to assess efficacy and safety of rimonabant 20 mg versus placebo on weight loss and frequency of binge episodes in obese patients with food craving.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Eating disorders; Obesity
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 14 Apr 2009 Actual end date (August 2005) added as reported by ClinicalTrials.gov.
    • 31 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top